<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02135185</url>
  </required_header>
  <id_info>
    <org_study_id>VA2011/43</org_study_id>
    <nct_id>NCT02135185</nct_id>
  </id_info>
  <brief_title>Effect of the Rehabilitation Effort at Home in Patients With Head and Neck Tumor Treated With Curative Intent</brief_title>
  <acronym>NUTRIMOUV</acronym>
  <official_title>Phase II Study, Multicentric, Randomized Studying the Effect of the Rehabilitation Effort at Home in Patients With Head and Neck Tumor Treated With Curative Intent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvement exercise tolerance
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study allows improved exercise tolerance in patients undergoing rehabilitation effort
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of the increase of initial endurance</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Patients increasing rate of at least 40% of their initial endurance time 3 months after the completion of radiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months after the end of radiotherapy</time_frame>
    <description>Quality of life 3 months after the end of radiotherapy (QLQ C30 and SF 36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months after the end of radiotherapy</time_frame>
    <description>&quot;Performance status&quot; (Karnofsky) 3 months after the end of radiotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months after the end of radiotherapy</time_frame>
    <description>Quantity of daily physical activity to 3 months after the end of radiotherapy (Actimeter).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months after the end of radiotherapy</time_frame>
    <description>Decrease addiction to 3 months after the end of radiotherapy (Declarative).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months after the end of radiotherapy</time_frame>
    <description>Rate of feasibility of the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months after the end of radiotherapy</time_frame>
    <description>Identification of indicator (s) to monitor the APA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months after the end of radiotherapy</time_frame>
    <description>Evaluation of precariousness (EPICES).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Rehabilitation effort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>custom work endurance combining dietary management adapted to the nutritional status and an APA. Included patients benefit from support for 19 weeks from the start of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control with dietary management adapted to the nutritional status</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>custom work endurance</intervention_name>
    <description>Experimental: Rehabilitation effort</description>
    <arm_group_label>Rehabilitation effort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>dietary management adapted to the nutritional status</intervention_name>
    <description>dietary management adapted to the nutritional status</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tumor squamous cell head and neck (excluding nasopharynx) nonmetastatic including
             cervical lymphadenopathy primitives

          -  Patient to be treated with curative radiotherapy monofractionnée for at least 6 weeks,
             with or without concurrent chemotherapy (including targeted therapies)

          -  KPS ≥ 60

        Exclusion Criteria:

          -  Cancer of the nasopharynx

          -  Metastatic Patient

          -  Patients who received neoadjuvant chemotherapy or induction

          -  Patient parenteral nutrition

          -  Non-compliant Patient Treatment

          -  Patient with a cons-indication to the achievement of an effort: clinical signs of
             pulmonary arterial hypertension (PAH) uncontrolled heart failure, recent myocardial
             infarction, arrhythmias, unstable angina.

          -  Patient desaturation in the stress test

          -  Patient already included in another clinical trial with an experimental molecule

          -  Pacemaker or defibrillator or neurostimulator

          -  Contraindications to treatment with standard radiotherapy with or without concurrent
             chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre SENESSE</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut régional du Cancer - Montpellier - Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

